Biosonics Inc., Expands Marketing Effort for Salitron With Physicians in East Region; Medical solutions company names manager of medical sales.

FT. WASHINGTON, Pa.--(BW HealthWire)--June 29, 1999--

Biosonics Inc. (OTC BB:BISN), of Fort Washington, is accelerating its marketing efforts in the Mid-Atlantic States to make more physicians, dentists and specialists aware of its Salitron System for the treatment of dry mouth, it was announced today by Jack Paller, President and CEO of the electro-therapeutic medical solutions company.

Sandra Pileggi, Vice President of Biosonics, said the aggressive Eastern Regional sales campaign will originate in the Philadelphia tri-state area for the Salitron System, which has been approved by the FDA for marketing for Sjogren's syndrome, an immune deficiency that causes xerostomia (dry mouth). Biosonics' Salitron System is the first safe, natural, effective treatment for this condition.

The Salitron is prescribed by physicians to reflexly stimulate the flow of saliva through cranial nerve pathways. It is the only natural therapeutic device available to dry mouth sufferers, which provides relief for longer periods of time without surgery, adverse side effects or drug interaction.

Coordination of the marketing campaign will be the responsibility of Karen Fonville, who has been promoted to the newly created position of Manager of Medical Sales.

"Karen Fonville has been an important staff member on our Biosonics team," according to Paller. "She has been coordinating corporate sales communications with physicians and customers, and is thoroughly conversant on our products, our services and our company. I know she will be an asset in our current efforts to expand marketing efforts to physicians, dentists and specialists."

"Karen interacts with our customers and physicians on a daily basis. She is working with me and our strategic marketing group to expose the Salitron System to more physicians at their offices. Karen is creative, resourceful and brings hands-on experience to the table," said Sandra Pileggi, Vice President of Biosonics.

In addition to the Salitron, Biosonics has developed other safe, natural, non-drug diagnostic products that are approved by the FDA for commercial distribution - the Cystotron for urinary and fecal incontinence and the BIDDS Glove, a diagnostic tool to be used by the physician to predetermine the effectiveness of the Cystotron.

All statements contained in this news release are not historical facts, including but not limited to the Company's plans for product development and marketing, but are based on current expectations. These statements are forward looking (as defined in the U.S. Private Securities Litigation Reform Act of 1995 and the Act) in nature and involve a number of risks and uncertainties.

The factors that could cause actual results to vary materially include the availability of capital to finance operations on terms satisfactory to the Company and the availability of clearances or approvals of products by federal, state and governmental authorities.